Natural Products Laboratory, Department of Bioengineering, Integral University, Dasauli, Kursi Road, Lucknow- 226026, Uttar Pradesh, India.
Med Chem. 2020;16(3):350-357. doi: 10.2174/1573406415666190416165732.
Currently, a novel antagonist against p38 is being designed and applied to inhibit hepatocellular carcinoma. Protein-ligand interaction plays a major role in the identification of the possible mechanism for the pharmacological action. The involvement of p38 remains an important target for anticancer drug development as its activation induces apoptosis in hepatoma cells.
The aim is to identify the best candidate from the plants of N. sativa which binds with the hepatocellular carcinoma (HCC) targets by computational approach.
The reported phytoconstituents such as thymoquinone and thymol present in the plant, N. sativa were docked with the HCC target such as p38. Structures of phytoconstituents were prepared using ChemDraw Ultra 10 software and converted into its 3D PDB structure and minimized using Discovery Studio client 2.5. The target protein, p38 was retrieved from RCSB PDB. Lipinski's rule and ADMET toxicity profiling were carried out on the phytoconstituents of the N. sativa, and the compounds were further promoted for molecular docking and MD simulation analysis.
The docking results revealed promising inhibitory potential of thymoquinone against p38 with binding energy of -7.67 kcal/mole as compared to its known standard doxorubicin having binding energy of -6.68 kcal/mol respectively. Further, molecular dynamic (MD) simulations for 5ns were conducted for optimization, flexibility prediction, and determination of folded p38 stability. The p38-thymoquinone complex was found to be quite stable with RMSD value of 0.2 nm.
Obtained results propose thymoquinone binding energy on the selected targets. Hence, this compound bears outstanding potential against hepatocellular carcinoma and has to be taken up for experimental work against hepatocellular carcinoma.
目前,一种新型的 p38 拮抗剂正在被设计并应用于抑制肝癌。蛋白质-配体相互作用在鉴定药理作用的可能机制方面起着重要作用。p38 的激活诱导肝癌细胞凋亡,因此其激活仍然是抗癌药物开发的重要靶点。
本研究旨在通过计算方法从荠属植物中鉴定出与肝癌(HCC)靶点结合的最佳候选物。
报道的荠属植物中的植物化学成分,如存在于植物中的百里醌和百里酚,与 HCC 靶点(如 p38)对接。使用 ChemDraw Ultra 10 软件制备植物化学成分的结构,并将其转换为其 3D PDB 结构,并使用 Discovery Studio client 2.5 进行最小化。靶蛋白 p38 从 RCSB PDB 中检索。对荠属植物的植物化学成分进行 Lipinski 规则和 ADMET 毒性分析,并进一步促进其进行分子对接和 MD 模拟分析。
对接结果显示,与已知标准阿霉素( doxorubicin )的结合能(-6.68 kcal/mol)相比,百里醌对 p38 具有更好的抑制潜力,结合能为-7.67 kcal/mol。进一步进行了 5ns 的分子动力学(MD)模拟,以优化、预测灵活性和确定折叠 p38 的稳定性。发现 p38-百里醌复合物非常稳定,RMSD 值为 0.2nm。
研究结果表明百里醌与所选靶点的结合能。因此,该化合物对肝癌具有显著的潜在作用,需要进行针对肝癌的实验研究。